Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome

ABSTRACT Lung cancer treatment has evolved at the molecular level. Detecting the presence of driver genes in lung cancer fundamentally alters the choice of therapeutic regimens and the outcome of this disease. ALK fusion mutation is one of the most important mutations in nonsmall cell lung cancer (N...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingyuan Du, Cuiwei Liu, Leichong Chen, Zhenyu Li, Sijia Zhang, Rui Meng
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:The Clinical Respiratory Journal
Subjects:
ALK fusion
concomitant
EGFR mutation
NSCLC
TP53 mutation
Online Access:https://doi.org/10.1111/crj.70041
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items